Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
CONCLUSIONSUnlike patients with melanoma, patients with NSCLC with brain metastases undergoing SRS showed no significant benefit-either in terms of survival or total amount of lesional response-when anti-PD-1 therapies were used. However, in lesions with volume > 500 mm3, combining SRS with IT may result in a faster and better volumetric response which may be particularly beneficial in lesions causing mass effect or located in neurologically critical locations.
PMID: 30771783 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Singh C, Qian JM, Yu JB, Chiang VL Tags: J Neurosurg Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Melanoma | Neurology | Neurosurgery | Non-Small Cell Lung Cancer | Skin Cancer | Study